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ABSTRACT  
Background: Clopidogrel/aspirin antiplatelet therapy routinely is administered 7-10 
days before pipeline aneurysm treatment. Our study assessed the safety and efficacy 
of a 600-mg loading dose of clopidogrel 24 hours before Pipeline Embolization Device 
(PED) treatment. 
Methods: In this retrospective cohort study, we included patients treated with PED 
from October 2010 to May 2016. A total of 39.7% (n = 158) of patients were dispensed 
a loading dose of 650 mg of aspirin plus at least 600 mg of clopidogrel 24 hours 
preceding PED deployment, compared to 60.3% (n = 240) of patients who received 
81-325 mg of aspirin daily for 10 days with 75 mg of clopidogrel daily preprocedurally. 
The mean follow-up was 15.8 months (standard deviation [SD] 12.4 months). modified 
Rankin Scale (mRS) was registered before the discharge and at each follow-up visit. To 
control confounding, we used multivariable logistic regression and propensity score 
conditioning. 
Results: Of 398 patients, the proportion of female patients was ~16.5% (41/240) in 
both groups and shared the same mean of age ~56.46 years. ~12.2% (mean = 0.09; 
SD = 0.30) had a subarachnoid hemorrhage. 92% (mean = 0.29; SD = 0.70) from the 
pretreatment group and 85.7% (mean = 0.44; SD = 0.91) of the bolus group had a 
mRS ≤2. In multivariate analysis, bolus did not affect the mRS score, P = 0.24. Seven 
patients had a long-term recurrence, 2 (0.83%; mean = 0.01; SD = 0.10) of which from 
the pretreatment group. In a multivariable logistic regression, bolus was not associated 
with a long-term recurrence rate (odds ratio [OR] 1.91; 95% confidence interval [CI] 
0.27-13.50; P = 0.52) or with thromboembolic accidents (OR 0.99; 95% CI 0.96-1.03; 
P = 0.83) nor with hemorrhagic events (OR 1.00; 95% CI 0.97-1.03; P = 0.99). Three 
patients died: one who received a bolus had an acute subarachnoid hemorrhage. 
The mean mortality rate was parallel in both groups ~0.25 (SD = 0.16). Bolus was not 
associated with mortality (OR 1.11; 95% CI 0.26-4.65; P = 0.89). The same associations 
were present in propensity score-adjusted models. 
Conclusions: In a cohort receiving PED, a 600-mg loading dose of clopidogrel should 
be safe and efficacious in those off the standard protocol or showing <30% platelet 
inhibition before treatment. 
INTRODUCTION 
Pipeline embolization device (PED; Covidien, Irvine, California, USA) has become an 
integral tool in the treatment of intracranial aneurysms. Since its approval by the Food 
and Drug Administration in 2011, studies have publicized remarkable occlusion rates 
with this endoluminal device.1 Antiaggregation drugs are dispensed during and after the 
pipeline deployment procedure to reduce the likelihood of thromboembolic events.2 
A single loading dose of aspirin or clopidogrel is neither safe nor sufficient in reducing 
PED-related thromboembolic complications.3 Patients suffering from cerebrovascular 
aneurysms and selected for a flow diversion treatment should receive a dual antiplatelet 
therapy (DAPT) of aspirin and clopidogrel 
for a minimum of 7-10 days before the 
intervention.4 Even at a high maintenance 
dose, patients continue to show variability 
in the degree of platelet inhibition.5 
The key in approaching cerebral 
aneurysms is in assuring an optimal 
>50% platelet inhibition with the right 
choice of antiplatelet medication and 
by keeping the platelet-reactive units 
(PRUs) between 194 and 416 (adopted in 
our center).6 Although a standard 75-mg 
dose of clopidogrel produces an irrevers-
ible P2Y12 platelet receptor blockade, its 
72-hour delayed maximal action is one 
of its major limitations.7 A bolus of 600 
mg of clopidogrel must be administered 
to overcome the previous limitation and 
achieve a rapid and more potent platelet 
inhibition within 24 hours before the 
pipeline deployment.8 The central aim of 
this study was to evaluate the safety and 
the efficacy of a 600-mg loading dose of 
clopidogrel when given 24 hours before 
PED deployment to protect patients from 
thromboembolic events during and after 
their procedure. 
METHODS
Study Population 
This was a retrospective cohort study of 
all patients undergoing a PED treatment 
for their cerebrovascular aneurysms in a 
tertiary referral center between October 
2010 and May 2016. A total of 398 
consecutive patients undergoing pipeline 
flow diversion were included. The mean 
age of the population was 56.46 years 
(min = 16 years, max = 81 years). Only 2 
patients were minors at 16 and 17 years 
old. The study protocol was reviewed 
and approved by the institutional review 
board. Patient consent was not needed 
because of the retrospective nature of 
the study. A total of 23 of 398 patients 
presented with ruptured aneurysm.
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Outcome Variables 
The key primary outcomes were throm-
boembolic event incidence (minor: 
transient deficit or asymptomatic stroke 
documented on diffusion-weighted 
imaging; major: clinically measurable 
deficit) including pre- and postprocedural 
thrombus formation and hemorrhagic 
accidents with subsequent tangible and 
concrete clinical deficit (not including 
the asymptomatic sulcal SAH as seen 
on routine postoperational computed 
tomography) after pipeline deployment. 
Early and late postprocedural hemor-
rhagic and thromboembolic events 
were included. Modified Rankin Scale 
(mRS) score, calculated and registered 
before the discharge of the patients and 
at each follow-up visit, mortality rates, 
intrapipeline stenosis due to overt neoen-
dothelialization, postinterventional length 
of stay, and the long-term recurrence 
were all considered secondary outcomes.
Patient Follow-Up 
Follow-up visits were scheduled with 
the senior author after 1, 3, 6, and 
18 months after their discharge from 
Treatment Protocol 
Patients treated with the PED were 
analyzed retrospectively and separated 
into two groups of standard of care 
treatment, i.e., 158 (39.7%) patients were 
administered a DAPT bolus of 650 mg 
of aspirin plus at least 600 mg of clopi-
dogrel within the 24 hours preceding 
their procedure and 240 (60.3%) patients 
(227 with aspirin, 9 with coumadin, 4 
with rivaroxaban) received the standard 
protocol of 81-325 mg of aspirin daily 
with 75 mg of clopidogrel daily for 7-10 
days before their intervention. Patients 
included in both groups were recruited 
subsequent to an incidental finding 
of their aneurysm on routine neuro-
imaging or to a screening magnetic 
resonance angiography prescribed 
because of first-degree family history 
of aneurysms. Others had symptoms 
related to the aneurysm: worst headache 
of life, Horner syndrome, worsening 
headache, ophthalmoplegia, dizziness, 
tinnitus, blurry vision, diplopia, and retro-
orbital pain. A total of 23 (5.8%) patients 
were admitted urgently and diagnosed 
with a subarachnoid hemorrhage (SAH) 
secondary to aneurysm rupture: 6 (26%) 
were pretreated with aspirin and clopi-
dogrel, and 1 7 (74%) was administered 
a bolus of DAPT as described previously. 
We regularly calculated the P2Y12 PRU 
score using P2Y12 assays (VerifyNow; 
Accumetrics, San Diego, California, USA) 
for all patients before the procedure. 
Prasugrel (n = 20) was considered if the 
patients were allergic, nonresponders, or 
resistant to clopidogrel. Resistance was 
defined with <30%, PRU <194 of platelets’ 
P2Y12 receptor inhibition with antiplatelet 
drugs. Ticagrelor (n = 2) was adopted in 
patients labeled as non- responders or 
allergic to prasugrel. Patients with inhibi-
tion >90% had their procedure canceled, 
and clopidogrel was held until the platelet 
inhibition level fell below 90%. Patients 
were continued afterword on 75 mg of 
clopidogrel daily or 5-10 mg of prasugrel 
daily or 90 mg twice a day of ticagrelor 
daily. Vitals and neurologic examination 
were monitored in the intensive care unit, 
and patients were deescalated to the 
floor after 24 hours of clinical well-being. 
Prophylactic antiplatelet therapy was 
given as a minimum of 6 months to 1 year 
after the procedure, followed by aspirin 
indefinitely (Figure 1). 
the institution. The efficacy and the 
safety of the aspirin/clopidogrel bolus 
dispensed within 24 hours preceding 
the pipeline treatment was evaluated 
on initial postoperative angiography. 
Cerebrovascular angiography (digital 
subtraction angiography) was required 
at the 6-month visit, and then patients 
were followed accordingly to evaluate 
for bleeding recurrence or vessel 
stenosis. Computed tomography 
scans of the head were compared 
and analyzed by the senior author 
to document any new or recurrent 
subarachnoid or intraparenchymal 
hemorrhage only if the patients 
developed new insidious symptoms. 
Medical charts were reviewed to 
determine whether any retroperito-
neal, gastrointestinal, or genitourinary 
bleeding had occurred. 
Exposure Variables 
The primary exposure variable was the 
treatment (clopidogrel pretreatment vs. 
clopidogrel bolus). Covariates used for 
risk adjustment were age and sex. The 
comorbidities used for risk adjustment 
Figure 1.  Decision tree graph of the antiaggregation Pipeline Embolization Device;  
PRU, platelet-reactive protocol adopted before pipeline deployment. PED, unit.
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SD = 0.19) in the pretreatment group 
versus 13.3% (20/158; mean = 0.12; SD 
= 0.33) in patients receiving the loading 
dose of antiaggregate medication (P = 
0.75). Balloon angioplasty was needed in 
approximately 9.7% (22/240; 16/158) of 
patients in both groups (P = 0.90). Nine 
of 158 patients from the bolus group 
presented with aneurysm rupture and a 
subsequent SAH and required an imme-
diate intervention with a loading dose of 
clopidogrel. A total of 139 of 158 patients 
were included because of nonrespon-
siveness or resistance to the standard 
10 days DAPT antiaggregation protocol. 
The mean monthly follow-up for the 
patients was 15.8 months (SD = 12.36). A 
total of 398 patients were identified at our 
institution, and they constituted our study 
population. The characteristics of the 
cohort at baseline are disclosed in Table 1. 
Safety of a Loading Dose of 
Clopidogrel
Thromboembolic Complications. Of 398 
patients, 15 (6.3%; mean = 0.05; SD = 
0.23) patients receiving the pretreat-
ment protocol had thromboembolic 
complications, and 17 (10.8%; me 
an = 0.12; SD = 0.32) patients from 
the bolus group suffered from these 
complications (Table 2). A univariate 
analysis comparing the use of a bolus 
of clopidogrel with the thrombo-
embolic complication rate did not 
show any correlation between the 2 
variables (odds ratio [OR], 0.99; 95% 
confidence interval [CI] 0.96-1.03; P 
= 0.83). We found similar results in a 
multivariable mixed-effects logistic 
regression bolus (OR 0.99; 95% CI 
0.96-1.03; P = 0.81) and a propensity 
score-adjusted model (OR 0.99; 95% 
CI 0.96-1.03; P = 0.82).
Hemorrhagic Complications. Of 398 
patients, 9 (3.75%; mean = 0.25; SD = 
0.16) (Table 2) patients receiving the 
pretreatment protocol had hemor-
rhagic complications, and 12 (7.6%; 
mean = 0.08; SD = 0.27) patients from 
the bolus group suffered from these 
complications. The mean of hemor-
rhagic complications in the global 
population was 0.48 (SD = 0.21). A 
univariate analysis comparing the 
use of a bolus of clopidogrel with the 
hemorrhagic complication rate did not 
show any correlation between the 2 
Regression diagnostics were 
performed for all analyses. Given that 
the long-term recurrence was 2% in a 
study sample of 437 patients, we had 
an 80% power to detect a difference 
in long-term recurrence as small as 
13.4%, at an α-level of 0.05. All prob-
ability values were the result of two 
sided tests. Stata version 13 (StataCorp, 
College Station, Texas, USA) was used 
for statistical analysis. 
RESULTS
Demographic Characteristics 
Between October 2010 and May 2016, 
398 patients underwent treatment with 
PED in our institution. The proportion of 
female patients was 17.1% (41/240) in the 
pretreatment group and 15.8% (25/158) 
in the bolus group (P = 0.30). Patients in 
the pretreatment group shared a similar 
mean of age with the bolus group (56.15 
years; 56.77 years), respectively (P = 
0.510). The mean aneurysm size was 9.22 
mm (standard deviation [SD] = 6.04) in 
the pretreatment group and 9.58 mm (SD 
= 6.84) in the bolus group (P = 2.86). The 
proportion of patients with a history of 
previous SAH (not presenting with acute 
SAH) was 11.7% (28/240; mean = 0.09; 
SD = 0.30) in the pretreatment group, 
whereas it was 12.7% (20/158; mean = 
0.10; SD = 0.30) in the bolus group (P = 
0.92). Likewise, both groups had the same 
average 1.21 (min = 1 PED, max = 4 PED) 
number of pipelines used per patient. The 
fraction of patients receiving adjunctive 
coiling was 4.6% (11/240; mean = 0.41; 
were hypertension, diabetes mellitus, 
smoking, previous SAH, aneurysm 
size, per-procedural balloon, previous 
coiling. This manuscript adheres to the 
Strengthening the Reporting of Obser-
vational studies in Epidemiology (i.e., 
STROBE) Statement: guidelines for 
reporting observational studies. 
Statistical Analysis 
For binary outcomes we used a multi-
variable logistic regression, controlling 
for all the covariates mentioned previ-
ously. To control for clustering at the 
physician level, we used mixed effect 
models with physician as a random 
effects variable. For continuous 
outcomes, we used the corresponding 
linear regression analyses. 
In an alternate way to control for 
confounding for binary outcomes, 
we used a propensity score adjusted 
logistic regression model. To derive 
the propensity of receiving a bolus, we 
developed a prediction model using 
logistic regression, based on all the 
covariates described previously. We 
subsequently used a logistic regres-
sion with adjustment (stratification) 
by quantiles (we chose the number of 
quantiles to be 10) of the propensity 
score. Operating physician was again 
used as a random effects variable. 
Patients who were lost to follow-up 
were not included in the original 
analysis. In sensitivity analysis, all 
the aforementioned analyses were 
repeated used multiple imputations 
for the patients lost to follow-up. 
Table 1.  Patient characteristics
Bolus
p value
Yes (n=158) No (n=240)
Age (years) 56.77 (13.70) 56.15 (13.04) 0.51
Male gender 84.2% 82.9% 0.30
Hypertension 0.53 (0.50) 0.49 (0,50) 0.83
Smoking 0.52 (0.50) 0.49 (0,50) 0.31
Aneurysm size (mm) 9.58 (6.84) 9.23 (6.04) 2.86
Previous SAH* 0.10 (0.30) 0.10 (0.23) 0.92
Adjunctive Coiling 0.12 (0.33) 0.04 (0.20) 0.75
Balloon use 0.07 (0.26) 0.07 (0.26) 0.90
*SAH, subarachnoid hemorrhage.
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variables (OR 0.99; 95% CI 0.97-1.03; 
P = 0.87). In a multivariable mixed-
effects logistic regression, bolus (OR 
1.00; 95% CI 0.97-1.03; P = 0.99) was 
not associated with an increased 
hemorrhagic event rate. We found 
similar results with the propensity 
score adjusted model (OR 0.99; 95% 
CI 0.96-1.03; P = 0.87).
Long-Term Recurrence. Of 398, 
7 (1.76%; mean = 0.02; SD = 0.15) 
patients had a long-term recurrence: 2 
(0.83%; mean = 0.01; SD = 0.10) from the 
pretreatment group versus 5 (3.16%; 
mean = 0.03; SD = 0.18) patients in 
the bolus group. A univariate analysis 
comparing the use of a bolus of clopi-
dogrel to the long-term recurrence 
rate did not show any correlation 
between the 2 variables (OR 3.32; 95% 
CI 0.60-18.43; P = 0.17). In a multivari-
able mixed-effects logistic regression, 
bolus (OR 1.91; 95% CI 0.27-13.50; P = 
0.52) was not associated with a long-
term recurrence rate. This finding was 
consistent with the propensity score-
eadjusted model (OR 3.00; 95% CI 
0.51-17.58; P = 0.22) (Table 3).
Mortality. Of 398 patients, 9 patients 
expired: 6 patients died from various 
non-PED related events such as severe 
sepsis (1), malignant hypertension with 
a large middle cerebral artery infarct 
(1), severe gastro-intestinal complica-
tion (1), and non-reported (3). Only 
three patients were announced dead 
secondary to cerebrovascular compli-
cations: one patient from the bolus 
group died from acute SAH, and two 
patients from the pretreatment group 
died from severe intraparenchymal 
hemorrhage. The mean of mortality 
rate in the global population was 
0.02 (SD = 0.15), 0.25 (SD = 0.16) in 
the pretreatment group, and 0.26 (SD 
= 0.16) in the bolus group (Table 2). 
A univariate analysis comparing the 
use of a bolus of clopidogrel to the 
mortality rate did not show any corre-
lation between the two variables (OR 
0.99; 95% CI 0.77-1.30; P = 0.95). In 
a multivariable mixed-effects logistic 
regression, bolus (OR 1.11; 95% CI 
0.26-4.65; P = 0.89) was not associ-
ated with an increased mortality rate. 
This finding persisted in a propensity 
score-adjusted model (OR 0.99; 95% 
CI 0.89-1.11; P = 0.92).
Efficacy of the Loading Dose of 
Clopidogrel
Intrapipeline Stenosis. Of 398 patients, 
27 (6.8%; mean = 0.75; SD = 0.26) had an 
intra-PED stenosis with 17 (7.08%; mean = 
0.72; SD = 0.26) in the pretreatment group 
and 10 (6.32%; mean = 0.76; SD = 0.27) 
in the bolus group. A univariate analysis 
comparing the use of a bolus of clopido-
grel with the intrapipeline stenosis rate 
did not show any correlation between the 
two variables (OR 1.07; 95% CI 0.45-2.55; 
P = 0.88). In a multivariate mixed-effects 
logistic regression, bolus (OR, 0.90; 95% 
CI 0.36-2.30; P = 0.89) was not associ-
ated with higher intra-PED stenosis rate. 
This was coherent with the propensity 
score-adjusted model. (OR 0.92; 95% CI 
0.37-2.34; P = 0.88). 
Latest Clinical Status. In the global popu-
lation, the mean mRS was 0.36 (SD = 0.79); 
it was 0.44 (SD = 0.91) in the bolus group 
and 0.29 (SD = 0.70) in the pretreatment 
group. A total of 87.8% of the global popu-
lation, 92% of the pretreatment group and 
85.7% of the bolus group had a mRS 2. In a 
multivariate analysis were the latest mRS is 
a dependent variable, bolus did not affect 
the latest mRS score, P = 0.24 (Table 3). 
Postinterventional Hospital Stay. In the 
global population, the mean postopera-
tional hospital stay was 1.86 days (SD = 
2.96): 1.69 days (SD = 2.81) in the pretreat-
ment group and 2.11 days (SD = 3.2) in 
the bolus group. In a multivariate analysis 
in which the postinterventional stay is a 
dependent variable, bolus did not affect 
the postoperational hospital stay, P = 0.64. 
Table 2. Mean Value and Standard Deviation of Outcomes  
Outcomes
Pre-treatment 
mean(SD*)
Bolus 
mean(SD*)
Total  
mean(SD*)
Long-term recurrence .11 (0.10) .34 (0.2) .21 (0.14)
Intra-PED stenosis .07 (0.26) n=17 0.07 (0.26) n=10 .07 (0.26)
Thromboembolic acc. .54 (0.23) n=2 .12 (0.32) n=5 .07 (0.26)
Hemorrhagic acc. .25 (0.16) .10 (0.28 .41 (0.28)
Mortality .25 (0.16) .25 (0.16) .02 (0.15)
Length of stay(days) 1.69 (2.81) 2.11 (3.2) 1.86 (2.96)
mRS at last follow-up .44 (0.91) .29 (0.7) .36 (0.79)
Table 3. Aassociation Between Outcomes and Clopidogrel Bolus
Models
Long-term recurrence 
OR*(CI95%)   p value
Intra-PED stenosis 
OR*(CI95%)   p value
Thromboembolic 
OR*(CI95%)   p value
Hemorrhagic 
OR*(CI95%)   p value
Mortality 
OR*(CI95%)   p value
Multi-variable  
logistic regression
1.9 1 
(.27 to 13.50)
0.517
0.90  
(.36 to 2.29)
0.83
0.99 
(.96 to 1.03)
0.81
1.00  
(.97 to 1.03)
0.99
1.11 
(.26 to 4.65)
0.89
Propensity score 
3.00  
(.513 to 17.58)
0.22
0.928  
(.37 to 2.34)
0.88
0.99  
(.96 to 1.03)
0.82
0.99  
(.97 to 1.03)
0.87
0.99  
(.89 to 1.11)
0.92
Clopidogrel Loading Dose
*SD, standard deviation; PED, Pipeline Embolization Device; acc., accident; mRS, modified Rankin Scale.
*OR, odds ratio; CI, confidence interval.
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than the 300-mg loading dose given 24 
hours before the procedure. How- ever, 
the 600-mg loading dose given a day 
before PCI was not statistically inferior to 
the 300-mg/150-mg daily maintenance 
dose. 
The results from the Antiplatelet 
therapy for Reduction of Myocardial 
Damage during Angioplasty (ARMYDA-8 
RELOAD- ACS) trial have shown a statisti-
cally significant advantage of reloading 
patients with acute coronary syndrome 
who were already on chronic clopido-
grel therapy (75 mg) with a loading dose 
of 600 mg of clopidogrel before PCI.18 
The reloading strategy was associated 
with a 66% relative risk reduction of 
30-day major adverse cardiac events.18 
Whether this additional advantage is due 
exclusively to added inhibition of platelet 
aggregation is not well established. A 
study conducted by Patti et al.19 indicates 
that a clopidogrel loading dose (600 
mg or 300 mg) before PCI decreases 
procedural P-selectin levels. P-selectin 
is a marker of platelet activation and 
may directly contribute to the stability 
of platelet aggregates.20 It also may be 
partly responsible for mechanisms linking 
inflammation and thrombosis.21 This may 
suggest that the benefits of the loading 
dose strategy are not just exclusive to the 
inhibition of adenosine diphosphateein-
duced platelet aggregation. Many other 
studies demonstrated the advantage of 
giving a high-loading dose (600 mg) of 
clopidogrel before PCI compared with 
the standard 300-mg dose.19,22-24 Also, 
the clinical trial done by Nguyen et al. 
did not show any superiority of an even 
high pretreatment maintenance dose of 
clopidogrel preceded by 300-mg bolus 
1 week before PCI compared with the 
600-mg loading dose 1 day before the 
procedure.17 It is also noteworthy to 
mention that in our study population, 
<20% of the patients were female, and our 
overall aneurysm distribution by sex was 
not typically skewed towards males. We 
do not know how this finding could have 
affected our results. Further prospective 
studies are needed to uncover a possible 
association between sex and pipeline 
treatment complications. 
Whether all these results infer superi-
ority of the 600-mg loading dose of 
clopidogrel before PED to the 75-mg 
maintenance dose given a week before 
The rate of hemorrhagic complications 
in the clopidogrel bolus group was 7.6% 
compared with 3.75% in the clopido-
grel pretreatment maintenance dose. 
Leung et al.15 suggested that patients 
with acute ischemic strokes receiving 
clopidogrel loading doses within 24 
hours of symptom onset did not have 
a greater rate of new serious bleeding 
events compared with patients who did 
not receive loading doses. Nonetheless, 
we will wait the results of the Platelet-
Oriented Inhibition in New TIA and Minor 
Ischemic Stroke trial to confirm the safety 
of clopi- dogrel dosing in this group.16 
Nonetheless, 4 patients receiving bolus 
precipitated intracerebral hemorrhage 
postprocedurally. One died, and 3 had 
small right temporal and frontal bleeding, 
who ended up having minimal neurologic 
sequelae (mRS 2). Eight other patients 
from the same group manifested SAH 
postprocedurally. Three had minor SAH 
with minimal neurosequelae (mRS 2) on 
latest follow-up, and the remaining 5 
patients died subsequently due to major 
SAH: 2 of them died the first week after 
their intervention, and the last 3 died 1 or 
2 months postprocedurally. Even if our 
statistical analysis does not show any 
significant difference in hemorrhagic 
complication between both groups, it 
is noteworthy to emphasize the greater 
rate of hemorrhagic events in the bolus 
group. Whether the clopidogrel loading 
dose increased the rate of hemorrhage 
in our series cannot be inferred from 
our descriptive study design, and further 
prospective studies are needed for to 
confirm these observations. 
To our knowledge, there is only one study 
reflecting a head-to-head comparison 
between clopidogrel pretreatment 
protocol and high loading dose in cardio-
vascular literature, as percutaneous 
coronary intervention (PCI) is almost 
always done during emergencies.17 In 
this randomized, double-blinded, clinical 
trial, Nguyen et al.17 compared different 
maintenance doses of clopidogrel given 
a week before PCI (75 mg once daily vs. 
150 mg once daily after 300-mg loading 
dose each) and loading doses (300 mg 
vs. 600 mg) given 1 day before the proce-
dure. They concluded that a loading 
standard dose of 300 mg of clopidogrel 
followed by a 150-mg daily maintenance 
dose given a week before PCI achieved 
better platelet inhibition and low reactivity 
DISCUSSION
Using a retrospective cohort of patients 
treated for their cerebrovascular 
aneurysm(s), we did not find any asso-
ciation between a clopidogrel 600-mg 
loading dose and increased mortality 
rate, thromboembolic accidents, long-
term recurrence, intrapipeline stenosis, 
hemorrhagic events, mRS on last follow-
up, and postoperational length of stay. 
The elevated risk of acute and delayed 
thromboembolic complications associ-
ated with the PED necessitates the use 
of antiplatelet therapy.9 The use of DAPT 
instead of aspirin alone has been the 
most commonly used trend after being 
translated from the cardiology litera-
ture.10 Nevertheless, there is no standard 
protocol to define the dose, duration, and 
the combination of the antiplatelet drugs 
used in the setting of PED placement.11 
In our study, 10.8% of patients in the 
bolus group suffered from thromboem-
bolic complications compared with 6.3% 
of the maintenance group. A total of 17 
patients from the bolus group manifested 
with thromboembolic events within less 
than 1-month follow-up: only 4 of them 
had a major permanent neurologic 
deficit ranging from extremity weakness 
to complete hemiparesis, whereas the 
other 13 patients had minor transient 
neurologic symptoms, such as visual 
floaters, minimal limb weakness, and 
numbness or speech difficulty, that 
completely resolved on latest follow-up 
(mRS <1). The latter results are somehow 
predictable as they reflect the pharma-
codynamic properties of clopidogrel. 
Platelet function assays done ex vivo 
revealed a measurable antiplatelet effect 
starting within 60 minutes and reaching 
a maximum of antiplatelet inhibition 2 
hours after the 600-mg loading dose of 
clopidogrel.12-14 The rates of thrombo-
embolic events seen in the clopidogrel 
bolus group would be precipitated by the 
complex pathophysiology of thrombo-
embolic events even when the patient is 
under an optimal antiplatelet regimen. 
This clopidogrel regimen would be 
addressing one single step in the primary 
hemostasis (platelet aggregation) process 
and sometimes might turn out to be 
insufficient for complete and definite 
protection of the patient from these 
complications. 
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the procedure cannot be determined at 
this time. Most of the studies in which 
authors compared the efficacy and 
safety of different doses of clopidogrel 
were extrapolated from cardiac studies 
and cannot be directly translated to 
cerebrovascular settings. Also, no head-
to-head comparison was done between 
the 1-week pretreatment maintenance 
dose of clopidogrel with the 600-mg 
loading dose 24 hours before PED. This 
comparison was not done in the present 
study, and no definite conclusions can 
be derived at this point. Our study is 
the first descriptive observational study 
that compared the different outcomes 
between the 600-mg loading dose and 
the pretreatment 75-mg maintenance 
dose used in patients undergoing PED. 
Our study remains limited by the retro-
spective nature of the data collection: 
the patients were not selected randomly 
for bolus versus pretreatment. Such a 
limitation must be addressed in further 
large prospective studies. Although no 
direct clinical suggestions can be derived 
from this study, we believe it is a first step 
towards higher-evidence studies to come 
out with a standard regimen of DAPT. 
CONCLUSIONS 
Aspirin/clopidogrel DAPT routinely is 
recommended for patients 7e10 days 
before receiving neurovascular PED 
treatment. Never- theless, patients 
presenting with ruptured aneurysms, 
those who could have not received a 
standard 10 days DAPT protocol, or 
those showing nonsatisfactory platelet 
inhibition at admission can be selected 
for an acute antiaggregation protocol: 
a 600-mg loading dose of clopidogrel 
might be safe and efficacious in reaching 
the optimal platelet inhibition within 24 
hours of the pipeline deployment. 
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